Moving from Words to Action

An annual faux pas most companies make during Black history month is trying to emphasize their commitment to diversity and African American culture / history despite falling short in these efforts the remainder of the year.

While social research and corporate responsibility policies have embraced the significance and benefits of DEI, the initiatives necessary to bring about these systemic changes have not kept pace.

In the January/February issue of PM360, David Fleishman joins other industry thought leaders to share their thoughts on how to make the clinical trial process more efficient, easier and accessible to a wider group of patients. 

PRESS RELEASE

BBK Worldwide Launches TCN® Engage, a Disruptive Tech-Service Ecosystem for an Inclusive and Positive Clinical Trial Experience

Breakthrough Clinical Trial Support System Establishes a New Standard in Engagement

BBK Worldwide (BBK), the global leader in maximizing the clinical trial experience for patients and providers, today announced the launch of TCN^® Engage, a breakthrough engagement ecosystem dedicated to providing a full array of visit support services from the time a patient responds to an advertisement for a clinical trial opportunity through to their completion of the study.

Clinical trial patient recruitment saw a lot of advancements in 2022, from patient concierge programs to DEI enrollment strategies. But what’s in store for 2023? We asked six of our industry experts to weigh in with their predictions.

BBK's Clinical Cuisine™ was just selected as one of the most innovative products of 2022 by PM360, a leading industry publication for the pharmaceutical, biotech, medical device and diagnostics industries.

A first-of-its-kind service, Clinical Cuisine helps support patients and caregivers during clinical trial participation by removing the burden of meal planning and preparation.

According to the Centers for Disease Control and Prevention (CDC), among the top ten leading causes of death in the United States per year are diseases that include heart disease (696,962), cancer (602,350), stroke (160,264), Alzheimer’s disease (134,242) and diabetes (102,188).¹ It makes sense, then, that there would be substantial clinical efforts to provide preventative and curative treatments for these conditions. However, when planning your trial to test the efficacy of your treatment, how often do you reflect on the actual patient population?

The Necessity of Diverse and Inclusive Clinical Trials – And How to Get There*

Marginalized populations continue to be underrepresented in clinical trials — hurting both the relevance of scientific results and the quest for health equity. What can be done to overcome the mistrust many in these communities feel towards medical research, and to ensure they become fully invested participants in clinical trials?

Click here to read the full article in International Clinical Trials.

*Taken from International Clinical Trials, Autumn 2022, pages 16-20. © Samedan Ltd

In the September issue of PM360, Rob Laurens joins other industry thought leaders to share their opinions on what it takes today for life sciences companies to practice a patient-first approach.

BBK's patient recruitment campaign for Parkinson's disease has been selected as a finalist for the Pharmaceutical Executive APEX Awards

It's exciting times here at BBK! We are so thrilled to be recognized for our creative work on the Cerevel TemPo Studies website; developed to inform and prescreen patients newly diagnosed with Parkinson’s disease. We've been selected as a finalist for this year’s Pharmaceutical Executive APEX Awards — the only healthcare marketing awards judged entirely by HCPs. 

Catch Up on Our Content for Clinical Trial Sponsors

Featuring insights from industry thought leaders, our content provides clinical trial sponsors with knowledge and guidance to help navigate today’s challenging clinical trial patient recruitment and engagement environment.